OPTIMISMM Japanese Subgroup Analysis: Pomalidomide, Bortezomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

In Japan, pomalidomide (POM) in combination with dexamethasone (DEX) is approved for the treatment (Tx) of relapsed or refractory multiple myeloma. In the phase 3 OPTIMISMM trial (NCT01734928), pomalidomide, bortezomib, and dexamethasone (PVd) significantly improved progression-free survival (PFS) vs bortezomib and dexamethasone (Vd) (median, 11.2 vs 7.1 mos; HR 0.61; P < .0001) in the intent-to-treat population (100% lenalidomide [LEN] pretreated; 70% LEN refractory) who had 1 to 3 prior regimens. Here we report data for patients (pts) enrolled in Japan.